manganese (OTC)

Brand and Other Names:MnCl2
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 10mg (elemental)
  • 15mg (elemental)
  • 93mg (aspartate; 25mg elemental)
  • 50mg (gluconate; 5.7mg elemental)

capsule

  • 16.67mg

injectable solution

  • 0.1mg/mL

Adequate Intake

Male: 1.9-2.3 mg/day

Female: 1.6-1.8 mg/day

Pregnancy: 2 mg/day

Lactation: 2.6 mg/day

Prevention of Deficiency

Parenteral solution (TPN):150-800 mcg/day IV

Osteoporosis (Off-label)

5 mg PO qDay

Dosage Forms & Strengths

injectable solution: MnCl2

  • 0.1mg/mL

Adequate Intake

<6 months: 0.3-0.6 mg/day

6-12 months: 0.6-1.0 mg/day

1-3 years: 1.0-1.5 mg/day

3-8 years: 1.5-2.0 mg/day

8-13 years: 1.9 mg/day (males); 1.6 mg/day (females)

13-18 years: 2.2 mg/day (males); 1.6 mg/day (females)

Prevention of Deficiency

Parenteral solution (TPN): 2-10 mcg/kg/day IV  

Next:

Interactions

Interaction Checker

and manganese

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (1)

              • baloxavir marboxil

                manganese will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.

              Monitor Closely (3)

              • delafloxacin

                manganese will decrease the level or effect of delafloxacin by cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents.

              • omadacycline

                manganese will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.

              • sarecycline

                manganese will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.

              Minor (14)

              • calcium acetate

                calcium acetate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • calcium carbonate

                calcium carbonate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • calcium chloride

                calcium chloride, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • calcium citrate

                calcium citrate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • calcium gluconate

                calcium gluconate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • carbonyl iron

                carbonyl iron decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • ferric maltol

                ferric maltol decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • ferrous fumarate

                ferrous fumarate decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • ferrous gluconate

                ferrous gluconate decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • ferrous sulfate

                ferrous sulfate decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • iron dextran complex

                iron dextran complex decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • iron sucrose

                iron sucrose decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • polysaccharide iron

                polysaccharide iron decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • rose hips

                rose hips decreases levels of manganese by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Not well documented

              Previous
              Next:

              Warnings

              Contraindications

              Direct IV/IM injection administration (must dilute)

              Cautions

              May cause tissue damage if administered IV or IM directly due to very acidic solution (pH 2.0)

              Injection contains aluminum; use caution in renal impairment and premature infants

              Use caution in liver/biliary tract dysfunction, renal impairment (may need to decrease or withhold dose)

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: inj: C

              Lactation: Use caution

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Nutrition

              Sources

              Pineapples, almonds, oatmeal, chocolate, pumpkin seeds, whole wheat pasta, pecans, spinach

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Cofactor in many enzymes, incl superoxide dismutase (SOD, an antioxidant)

              Necessary for glycemic control, energy metabolism, thyroid hormone function

              May enhance bone turnover, cartilage synthesis

              Pharmacokinetics

              Absorption: Poor

              Distribution: Mitochondria of kidney, liver, pituitary gland, and bone

              Excretion: Bile (primarily); urine (negligible)

              Previous
              Next:

              Administration

              IV Info

              Dilute in at least 100 mL (do NOT use undiluted)

              Use promptly after mixing & in a single operation

              No preservatives-discard unused portion

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.